Lipid Metabolism During Pregnancy and its Implications for Fetal Growth

ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)

Volume 18, 15 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Biotechnology

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 152nd of 255 in Pharmacology & Pharmacy
  • 213th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Zeno Foldes-Papp
Urban Clinical Center Soltau
University teaching hospital of Hamburg

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.802
5 - Year: 2.327

Lipid Metabolism During Pregnancy and its Implications for Fetal Growth

Current Pharmaceutical Biotechnology, 15(1): 24-31.

Author(s): Emilio Herrera and Henar Ortega-Senovilla.

Affiliation: Universidad San Pablo CEU, Ctra. Boadilla del Monte km 5.3, 28668 Madrid, Spain.


More glucose crosses the placenta than any other substrate, but correlations between its concentration in maternal plasma and fetal growth are not found consistently. The accumulation of maternal fat depots and hyperlipidemia are the two principal changes in lipid metabolism during pregnancy. Although lipids cross the placenta with difficulty, maternal plasma triacylglycerols (TAG) and non-esterified fatty acids (NEFA) correlate with fetal lipids, fetal growth and fat mass under certain conditions. In intrauterine growth restriction, impaired placental transfer of lipophilic compounds (long-chain polyunsaturated fatty acids and lipophilic vitamins) seems to underpin metabolic dysfunction and decreased birth weight. In gestational diabetes mellitus (GDM), maternal TAG and NEFA levels correlate with neonatal anthropometric measures. In GDM, adipocyte fatty acid-binding protein in fetuses correlated with neonatal fat mass; changes in maternal or cord blood leptin, retinol binding protein 4 and adiponectin concentrations have been related to neonatal fat mass or birth weight, although their importance remains to be investigated. The angiopoietin-like protein 4 (ANGPTL-4) is secreted from adipose tissue, liver and placenta, and irreversibly inhibits lipoprotein lipase (LPL) activity. Maternal plasma ANGPTL-4 is decreased in GDM, and it has been proposed to be responsible for an increase in placental LPL activity, which would facilitate a greater fatty acid placental transfer, contributing to the higher fetal fat accumulation. Thus, while evidence suggesting major involvement of maternal lipid metabolism in fetal adiposity and growth exists, the precise mechanisms remain to be elucidated.


Adipocytokines, adipose tissue, gestational diabetes mellitus, hyperlipidemia, intrauterine growth restriction, nonesterified fatty acids, placenta, pregnancy.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 15
Issue Number: 1
First Page: 24
Last Page: 31
Page Count: 8
DOI: 10.2174/1389201015666140330192345
Pharmaceutical Microbiology 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science